These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 1671042)
1. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. Zabrecky JR; Lam T; McKenzie SJ; Carney W J Biol Chem; 1991 Jan; 266(3):1716-20. PubMed ID: 1671042 [TBL] [Abstract][Full Text] [Related]
2. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3. Alper O; Yamaguchi K; Hitomi J; Honda S; Matsushima T; Abe K Cell Growth Differ; 1990 Dec; 1(12):591-9. PubMed ID: 1981143 [TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965 [TBL] [Abstract][Full Text] [Related]
4. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Xu F; Lupu R; Rodriguez GC; Whitaker RS; Boente MP; Berchuck A; Yu Y; DeSombre KA; Boyer CM; Bast RC Int J Cancer; 1993 Feb; 53(3):401-8. PubMed ID: 7679090 [TBL] [Abstract][Full Text] [Related]
5. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001 [TBL] [Abstract][Full Text] [Related]
6. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Brodowicz T; Wiltschke C; Budinsky AC; Krainer M; Steger GG; Zielinski CC Int J Cancer; 1997 Dec; 73(6):875-9. PubMed ID: 9399669 [TBL] [Abstract][Full Text] [Related]
7. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro. Cao H; Decker S; Stern DF Oncogene; 1991 May; 6(5):705-11. PubMed ID: 1675782 [TBL] [Abstract][Full Text] [Related]
8. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322 [TBL] [Abstract][Full Text] [Related]
9. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Zhang H; Wang Q; Montone KT; Peavey JE; Drebin JA; Greene MI; Murali R Exp Mol Pathol; 1999 Sep; 67(1):15-25. PubMed ID: 10493889 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Drebin JA; Link VC; Greene MI Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329 [TBL] [Abstract][Full Text] [Related]
11. Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency. Srinivas U; Tagliabue E; Campiglio M; Ménard S; Colnaghi MI Cancer Immunol Immunother; 1993 Jun; 36(6):397-402. PubMed ID: 8098992 [TBL] [Abstract][Full Text] [Related]
12. Isolation of the intact molecule and ectodomain of C-erbB-2 oncoprotein from SK-BR-3 cells and development of immunoassays on microplate. Wu JT; Zhang P; Lyons BW; Wu LH J Clin Lab Anal; 1998; 12(5):298-303. PubMed ID: 9773962 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889 [TBL] [Abstract][Full Text] [Related]
14. Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. Tagliabue E; Castiglioni F; Ghirelli C; Modugno M; Asnaghi L; Somenzi G; Melani C; Ménard S J Biol Chem; 2000 Feb; 275(8):5388-94. PubMed ID: 10681513 [TBL] [Abstract][Full Text] [Related]
15. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). Liu B; Sun D; Xia W; Hung MC; Yu D J Natl Cancer Inst; 1997 Oct; 89(20):1524-9. PubMed ID: 9337349 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058 [TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line. Wu JT; Zhang P; Astill ME; Lyons BW; Wu LH J Clin Lab Anal; 1995; 9(3):141-50. PubMed ID: 7602422 [TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Müller V; Thomssen C; Karakas C; Eustermann I; Ramirez Porras J; Coith C; Berger J; Löning T; Jänicke F; Pantel K Int J Biol Markers; 2003; 18(1):13-20. PubMed ID: 12699058 [TBL] [Abstract][Full Text] [Related]
19. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. DiGiovanna MP; Stern DF Cancer Res; 1995 May; 55(9):1946-55. PubMed ID: 7728765 [TBL] [Abstract][Full Text] [Related]
20. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades. Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]